Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 4, 1998, Pages 453-464

  Hsu, Ann ^a   Granneman, G Richard ^b   Cao, Guoliang ^b   Carothers, Lori ^b   El Shourbagy, Tawalkol ^b   Baroldi, Paolo ^b   Erdman, Keith ^b   Brown, Fran ^b   Sun, Eugene ^b   Leonard, John M ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; REFERENCE VALUES; RITONAVIR; SAQUINAVIR;

EID: 7144257182     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90041-8     Document Type: Article

References (32)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD-4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
2. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1995;271:1582-6.
3. Markowitz M, Cao Y, Vesanen M, Talal A, Nixon D, Hurley A, et al. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor. Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Infectious Disease Society of America, Washington (DC). Abstract LB8.
4. Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine. Proceedings of the Third Conference on Retroviruses and Opportunistic Infections; January 28-Febraary 1, 1996; Infectious Disease Society of America, Washington (DC). Abstract LB7.
5. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. Safety, pharmacokinetics, and preliminary efficacy of RTV, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
6. Shapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, et al. The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV infected patients. Ann Intern Med 1996;124:1039-50.
7. Gulnik SV, Suvorov LI, Liu BS, Yu B, Anderson B, Mitsuya H, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995;34:9282-7.
8. Molla A, Granneman GR, Sun E, Kempf DJ. Recent developments in HIV protease inhibitor therapy. Antiviral Res [in press].
9. Saquinavir Product Information. Physician's desk reference. Montvale (NJ): Medical Economics; 1998.
10. Lea AP, Faulds D. Ritonavir. Drugs 1996;52:541-8.
11. Kempf D, Marsh KC, Denssen J, McDonald E, Vasavanonda S, Flentge C, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-8.
12. Cameron B, Heath-Choizzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV disease. Lancet 1998;351:543-9.
13. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-31.
14. Kempf DJ, Marsh KC, Kumar GN, Rodrigues AD, Denissen JF, McDonald E, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
15. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to RTV. Nature Med 1996;2:760-6.
16. Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological sampies using reversed-phase high-performance liquid chromatography. J Chromatography B 1997;704:307-13.
17. Sheiner LB, Beal S. Evaluation of methods for estimating population pharmacokinetic parameters; I: Michaelis-Menten model-routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980;8:553-71.
18. Orrego H, Mena I, Baraona E, Palma R. Modifications in hepatic blood flow and portal pressure produced by different diet. Am J Dig Dis 1965;10:239-48.
19. Kolars JC, Awni WM, Merion RM, Watkins PB. Firstpass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-90.
20. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
21. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
22. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Wrighton SA, Merion RM, et al. CYP 3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
23. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
24. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
25. Rowland M, Martin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1973;1:553-67.
26. Daneshmend TK, Roberts CJC. The effects of enzyme induction and enzyme inhibition on labetolol pharmacokinetics. Br J Clin Pharmacol 1984;18:393-400.
27. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and p-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34.
28. Washington CB, Duran GE, Sikic BI, Blaschke TF. Saquinavir is a high affinity substrate for the multidrag transporter, P-glycoprotein [abstract]. Clin Pharmacol Ther 1997;61:193.
29. Hoof T, Brandt T, Demmer A, Stellbrink HJ. Interaction of HIV protease inhibitors with MDR1: competitive binding and resistance modulation. Proceedings of the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada.
30. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41:898-905.
31. Hsu A, Granneman GR, Sun E, Chen P, El-Shourbagy T, Locke C, et al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir. Proceedings of the Eleventh International Conference on AIDS; 1996 Jul 7-12; Vancouver, British Columbia, Canada.
32. Granneman GR, Hsu A, Sun E, Leonard JM, Xu Y, Rode R, et al. Pharmacodynamics/pharmacokinetics of ritonavirsaquinavir combination therapy. Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Infectious Disease Society of America, Washington (DC).